The impact of therapeutic plasma exchange and double filtration plasmapheresis on hemostasis in renal transplant recipients


Cite item

Full Text

Abstract

Aim. To investigate the impact of double filtration plasmapheresis (DFPP) and therapeutic plasma exchange (TPE) on hemostasis in renal transplant recipients. Materials and methods. 54 renal transplant patients with an acute humoral rejection were treated with therapeutic apheresis methods: 24 patients with DFPP and 30 patients with TPE. In all patients was performed 3-4 session. We analyzed international normalized ratio (INR), activated partial thromboplastin time (APTT), fibrinogen concentration and platelet count just before and after each session, and after the course of all procedures. After TPE plasma replacement was performed with an equivalent volume of a fresh frozen plasma. After DFPP was performed 10-20% albumin solution. Results and discussion. After each DFPP session was occurred an increased INR and aPTT. After course of all DFPP procedures fibrinogen level decreased by 46%. It was associated with increase of APTT and INR by 35% and 32% respectively. Mainly it was associated with dose of the procedures (volume of plasma perfusion), but not with the plasma separator type. One patient noted hemorrhagic complication. After each TPE session level of fibrinogen concentration, INR and aPPT remained in the normal range, but there was a moderate reduction in platelet count, more pronounced than during DFPP. Hemorrhagic complications were not. Conclusion. Double cascade plasmapheresis and therapeutic plasma exchange generate preconditions for hemorrhagic complications such as increased aPTT and INR, reduce fibrinogen concentration. However, bleeding complications are rare. At the same time, during high volume DFPP should be careful when initially level of fibrinogen is low. In this case fibrinogen concentration should be controlled after the procedure for timely replenishment of its deficit.

About the authors

A V Vatazin

M.F. Vladimirskiy Moscow Regional Research and Clinical Institute

д.м.н., проф., руководитель отд. трансплантологии, нефрологии и хирургической гемокоррекции, зав. каф. трансплантологии, нефрологии и искусственных органов факультета усовершенствования врачей Moscow, Russia

A B Zulkarnaev

M.F. Vladimirskiy Moscow Regional Research and Clinical Institute

Email: 7059899@gmail.com
д.м.н., гл.н.с. хирургического отд-ния трансплантологии и диализа Moscow, Russia

References

  1. Bartel G, Schwaiger E, Böhmig G.A. Prevention and treatment of alloantibody - mediated kidney transplant rejection. Transplant Int. 2011;24(12):1142-55. doi: 10.1111/j.1432-2277.2011.01309.x
  2. Ruangkanchanasetr P, Satirapoj B, Termmathurapoj S, Namkhanisorn K, Suaywan K, Nimkietkajorn V, Luesutthiviboon L. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody - mediated rejection after kidney transplant. Exp Clin Transplant. 2014;12(4):328-33.
  3. Yamada C, Ramon D.S, Cascalho M, Sung R.S, Leichtman A.B, Samaniego M, Davenport R.D. Efficacy of plasmapheresis on donor - specific antibody reduction by HLA specificity in post - kidney transplant recipients. Transfusion. 2015;c55(4):727-35. doi: 10.1111/trf.12923
  4. Каабак М.М., Горяйнов В.А., Зокоев А.К. и др. Десятилетний опыт применения раннего плазмафереза после пересадки почки. Вестник трансплантологии и искусственных органов. 2009;11(1):28-33.
  5. Синютин А.А., Ватазин А.В., Зулькарнаев А.Б., Кантария Р., Крстич М. Применение плазмафереза для коррекции функциональных нарушений и расстройств микроциркуляции почечного аллотрансплантата в раннем послеоперационном периоде. Нефрология. 2013;17(4):83-8.
  6. Ward D.M. Conventional apheresis therapies: A review. J Clin Apheresis. 2011;26 (5):230-8. doi: 10.1002/jca.20302
  7. White B. Plasmapheresis in the treatment of acute vascular rejection: an experience on a dialysis unit. J Renal Care. 2006;32(4):208-9. doi: 10.1111/j.1755-6686.2006.tb00024.x
  8. Winters J.L. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematology. Am Soc Hematol Educ Program. 2012;2012:7-12. doi: 10.1182/asheducation-2012.1.7
  9. Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial. 2005;9(5):391-5.
  10. Bramlage C.P, Schröder K, Bramlage P, Ahrens K, Zapf A, Müller G.A, Koziolek M.J. Predictors of complications in therapeutic plasma exchange. J Clin Apher. 2009;24(6):225-31. doi: 10.1002/jca.20217
  11. Kaya E, Keklik M, Sencan M, Yilmaz M, Keskin A, Kiki I, Erkurt M.A, Sivgin S, Korkmaz S, Okan V, Doğu M.H, Unal A, Cetin M, Altuntaş F, Ilhan O. Therapeutic plasma exchange in patients with neurological diseases: multicenter retrospective analysis. Transfus Apher Sci. 2013;48(3):349-52. doi: 10.1016/j.transci.2013.04.015
  12. Чечеткин А.В., Семелев В.Н., Кононенко С.Н., Гусев С.В. Некоторые вопросы безопасности проведения автоматического тромбоцитафереза у доноров. Трансфузиология. 2010;11(3):12-9.
  13. Marks S. Therapeutic plasmapheresis: recognizing complications as soon as possible. Pflege Z. 2005;58(11):696-68.
  14. Blasi A, Cid J, Beltran J, Taurà P, Balust J, Lozano M. Coagulation profile after plasma exchange using albumin as a replacement solution measured by thromboelastometry. Vox Sang. 2016;110(2):159-65. doi: 10.1111/vox.12347
  15. Thölking G, Mesters R, Dittrich R, Pavenstädt H, Kümpers P, Reuter S. Assessment of Hemostasis after Plasma Exchange Using Rotational Thrombelastometry (ROTEM). PLoS One. 2015;10(6):e0130402. doi: 10.1371/journal.pone.0130402
  16. Zantek N.D, Morgan S, Zantek P.F, Mair D.C, Bowman R.J, Aysola A. Effect of therapeutic plasma exchange on coagulation parameters in patients on warfarin. J Clin Apher. 2014 Apr;29(2):75-82. doi: 10.1002/jca.21294. Epub 2013 Sep 2.
  17. Ibrahim R.B, Balogun R.A. Medications in patients treated with therapeutic plasma exchange: prescription dosage, timing, and drug overdose. Semin Dial. 2012;25(2):176-89. doi: 10.1111/j.1525-139X.2011.01030.x
  18. Lew S.Q. Amphotericin B removal by plasma exchange. J Clin Pharm Ther. 2009;34(1):115-7. doi: 10.1111/j.1365-2710.2008.00964.x
  19. Hanafusa N. Theoretical basis of pathogenic substance removal during plasmapheresis. Ther Apher Dial. 2011;15(5):421-30. doi: 10.1111/j. 1744-9987.2011.00930.x
  20. Kintzel P.E, Eastlund T, Calis K.A. Extracorporeal removal of antimicrobials during plasmapheresis. J Clin Apher. 2003;18(4):194-205.
  21. Okechukwu C.N, Meier-Kriesche H.U, Armstrong D, et al. Removal of basiliximab by plasmapheresis. Am J Kidney Dis. 2001;37(1):11. doi: 10.1016/S0272-6386(01)90008-3
  22. Nojima M, Yoshimoto T, Nakao A, et al. Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient Transplant Proc. 2005;37(2):875-8. doi: 10.1016/ j.transproceed.2005.01.050
  23. Puisset F, White-Koning M, Kamar N, Huart A, Haberer F, Blasco H, Le Guellec C, Lafont T, Grand A, Rostaing L, Chatelut E, Pourrat J. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody - mediated disease. Br J Clin Pharmacol. 2013;76(5):734-40. doi: 10.1111/bcp.12098
  24. Pruijm M.T, Vogt B, Cherpillod A. Plasmapheresis, a safe treatment when applied to the correct indication and with awareness of the complications. Ned Tijdschr Geneeskd. 2008;152(42):2261-6.
  25. Возгомент О.В. Свежезамороженная плазма как причина тяжелых аллергических осложнений, по данным экспертной оценки качества медицинской помощи. Трудный пациент. 2012;10(8-9):10-4.
  26. Stefanello B, De Paula E.V, Andrade Orsi F, Comenalli Marques J.F. Jr, Gasparotto Roveri E, Pereira Colella M, Castro Ozelo M, Maria Annichino-Bizzacchi J, Addas-Carvalho M. Safety and efficacy of cryoprecipitate - poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation. J Clin Apher. 2014;29(6):311-5. doi: 10.1002/ jca.21336
  27. Gungor O, Sen S, Kircelli F, et al. Plasmapheresis therapy in renal transplant patients: five - year experience. Transplant Proc. 2011;43(3):853-7.
  28. Higgins R, Lowe D, Hathaway M, et al. Double filtration plasmapheresis in antibody - incompatible kidney transplantation. Ther Apheres Dial. 2010;14(4):392-9. doi: 10.1111/j.1744-9987.2010.00821.x
  29. Han S, Hwang E, Park S, Park U, Kim H, Cho W. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double - filtration plasmapheresis. Exp Clin Transplant. 2014 Oct;12(5):401-4.
  30. Matsuo N, Yamamoto H, Kobayashi A, Yamamoto I, Mitome J, Maruyama Y, Hayakawa H, Miyazaki Y, Utsunomiya Y, Hosoya T, Yamaguchi Y. A case of accelerated acute rejection after ABO-compatible living unrelated kidney transplantation. Clin Transplant. 2009;23(20):23-6. doi: 10.1111/j.1399-0012.2009.01004.x
  31. Silvestre C, Furian L, Marson P, Tison T, Valente M, Marchini F, Rossi B, Bonfante L, Valerio F, Cozzi E, Rigotti P. Desensitization with plasmapheresis and anti-Cd20 for ABO incompatible kidney transplantation from living donor: experience of a single center in Italy. Transplant Proceed. 2014;46(7):2209-13. doi: 10.1016/j.transproceed.2014.07.063
  32. Uchida J, Iwai T, Kato M, Machida Y, Naganuma T, Kumada N, Yoshimura R, Kawashima H, Kim T, Nakatani T. A novel approach to successful ABO-incompatible high - titer renal transplantation. Transplant Proceed. 2008;40(7):2285-8. doi: 10.1016/j.transproceed.2008.06.018
  33. Tanabe K. Double - filtration plasmapheresis. Transplantation. 2007;84(12):30-2. doi:1097/01.tp.0000296103.34735.b8
  34. Ватазин А.В., Зулькарнаев А.Б., Кантария Р.О., Крстич М., Фаенко А.П. Особенности проведения плазмафереза при лечении отторжения почечного трансплантата. Вестник трансплантологии и искусственных органов. 2015;17(3):32-9.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies